Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
E Anders KolbPeter J HoughtonRaushan T KurmashevaYael P MosseJohn M MarisStephen W EricksonYuelong GuoBeverly A TeicherMalcolm A SmithRichard GorlickPublished in: Pediatric blood & cancer (2020)
AZD1775 potentiates the effects of irinotecan across most of the xenograft lines tested, with effect size appearing to vary across tumor panels.
Keyphrases